Ponatynib w leczeniu ostrej białaczki limfoblastycznej z obecnością chromosomu Filadelfia

Abstract

Acute lymphoblastic leukemia (ALL) with the presence of the Philadelphia chromosome (Ph+) is one of the most aggressive tumors. Improvement in the prognosis of patients occurred with the introduction of tyrosine kinase inhibitors (TKI), which are currently used in combination with chemotherapy. Such treatment is associated with over 90% chance of achieving complete remission. Next generations of TKI allow achieving deeper and longer responses, which translates into event-free and overall survival. Ponatinib (3 rd generation TKI) is currently registered in the treatment of patients with Ph(+) ALL after intolerance and/or resistance of first and second generation TKI or in patients with T315I mutation of BCR-ABL1 kinase. Work on assessing the efficacy and safety of ponatinib in the first line of therapy is ongoing.